EyeControl, a Tel Aviv, Israel-based supplier of assistive communication devices for ventilated and “locked-in” patients, raised $10m.
This is part of a Series A funding and of an Enhanced European Innovation Council’s (EIC) COVID-19 Pilot Program. The round was led by Connecticut Innovations, with participation from Benslie International Ltd, Clive Barret and Menomadin Foundation and existing investors Benny Levin (founder and former CEO of NICE), Itsik Danziger (former president of Comverse), Jim Elkind (private healthcare investor), Avi Kornreich (former CEO of Agentek), Zora Ventures, Impact First and Rimonci Capital.
The new funding will allow the company to grow by expanding its hospital activity and enhancing strategic partnerships.
Established in 2016 and led by Or Retzkin, CEO and co-founder, EyeControl provides a wearable, screenless assistive communication device based on AI-powered eye-tracking technology that enables remote communication between ventilated ICU patients, their families and medical care teams.
The EyeControl also improves quality of life for ventilated and locked-in home care patients, by providing round-the-clock communication with family members and caregivers. The device is CE marked, FDA listed and ISO certified. It is reimbursed by the U.S. Centers for Medicare and Medicaid Services, UK National Health Service and the Israeli Ministry of Health.
In addition to the funding, the company appointed digital health entrepreneur Avner Halperin as chairman of its newly expanded board of directors.